Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Abbott India Q3 net...

    Abbott India Q3 net profit rises at Rs 117 crore, revenue rises to Rs 947 crore

    GarimaWritten by Garima Published On 2019-02-10T09:30:26+05:30  |  Updated On 10 Feb 2019 9:30 AM IST
    Abbott India Q3 net profit rises at Rs 117 crore, revenue rises to Rs 947 crore

    Abbott India had posted a net profit of Rs 115.39 crore for the corresponding period of the previous financial year, Abbott India said in a filing to BSE.


    New Delhi: Drug firm Abbott India on Friday reported a marginal rise of 1.43 per cent in its net profit to Rs 117.05 crore for the third quarter ended December 31, 2018.


    The company had posted a net profit of Rs 115.39 crore for the corresponding period of the previous financial year, Abbott India said in a filing to BSE.


    Read Also: DOP directs NPPA to refix the ceiling price of Gentamicin based on Abbot application


    Revenue from operations of the company stood at Rs 947.65 crore for the quarter under consideration, as against Rs 881.49 crore for the same period year ago.


    Read Also: Abbot receives USFDA approval to Amplatzer Piccolo Occluder, smallest infant device to treat congenital heart defects

    Abbott IndiaAbbott India december 2018 profitAbbott India Q3Abbott India q3 earningsAbbott India q3 lossAbbott India Q3 net profitAbbott India q3 revenueAbbott India sharesAbbott India third quarter resultsBSEcompanies q3Drug firm Abbott Indiaq3 resultsrevenue risesShares of Abbott India
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok